| pubmed-article:2394002 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2394002 | lifeskim:mentions | umls-concept:C1257890 | lld:lifeskim |
| pubmed-article:2394002 | lifeskim:mentions | umls-concept:C0936044 | lld:lifeskim |
| pubmed-article:2394002 | lifeskim:mentions | umls-concept:C0155626 | lld:lifeskim |
| pubmed-article:2394002 | lifeskim:mentions | umls-concept:C0854571 | lld:lifeskim |
| pubmed-article:2394002 | lifeskim:mentions | umls-concept:C0035124 | lld:lifeskim |
| pubmed-article:2394002 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:2394002 | lifeskim:mentions | umls-concept:C0686907 | lld:lifeskim |
| pubmed-article:2394002 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:2394002 | pubmed:dateCreated | 1990-10-9 | lld:pubmed |
| pubmed-article:2394002 | pubmed:abstractText | To determine the clinical consequences of reocclusion of an infarct-related artery after reperfusion therapy, we evaluated 810 patients with acute myocardial infarction. Patients were admitted into four sequential studies with similar entry criteria in which patency of the infarct-related artery was assessed by coronary arteriography 90 minutes after onset of thrombolytic therapy. Successful reperfusion was established acutely in 733 patients. Thrombolytic therapy included tissue-type plasminogen activator (t-PA) in 517, urokinase in 87, and a combination of t-PA and urokinase in 129 patients. All patients received aspirin, intravenous heparin and nitroglycerin, and diltiazem during the recovery phase. A repeat coronary arteriogram was performed in 88% of patients at a median of 7 days after the onset of symptoms. Reocclusion of the infarct-related artery occurred in 91 patients (12.4%), and 58% of these were symptomatic. Angiographic characteristics at 90 minutes after thrombolytic therapy that were associated with reocclusion compared with sustained coronary artery patency were right coronary infarct-related artery (65% versus 44%, respectively) and Thrombolysis in Myocardial Infarction (TIMI) flow 0 or 1 (21% versus 10%, respectively) before further intervention. Median (interquartile value) degree of stenosis in the infarct-related artery at 90 minutes was similar between groups: 99% for reoccluded (value, 90/100%) compared with 95% for patent (value, 80/99%). Patients with reocclusion had similar left ventricular ejection fractions compared with patients with sustained patency at follow-up. However, patients with reocclusion at follow-up had worse infarct-zone function at -2.7 (value, -3.2/-1.8) versus -2.4 (SD/chord) (value, -3.1/-1.3) (p = 0.016). The recovery of both global and infarct-zone function was impaired by reocclusion of the infarct-related artery compared with maintained patency; median delta ejection fraction was -2 compared with 1 (p = 0.006) and median delta infarct-zone wall motion was -0.10 compared with 0.34 SD/chord (p = 0.011), respectively. In addition, patients with reocclusion had more complicated hospital courses and higher in-hospital mortality rates (11.0% versus 4.5%, respectively; p = 0.01). We conclude that reocclusion of the infarct-related artery after successful reperfusion is associated with substantial morbidity and mortality rates. Reocclusion is also detrimental to the functional recovery of both global and infarct-zone regional left ventricular function. Thus, new strategies in the postinfarction period need to be developed to prevent reocclusion of the infarct-related artery. | lld:pubmed |
| pubmed-article:2394002 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2394002 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2394002 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2394002 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2394002 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2394002 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2394002 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:2394002 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2394002 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2394002 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:2394002 | pubmed:issn | 0009-7322 | lld:pubmed |
| pubmed-article:2394002 | pubmed:author | pubmed-author:EllisSS | lld:pubmed |
| pubmed-article:2394002 | pubmed:author | pubmed-author:CaliffR MRM | lld:pubmed |
| pubmed-article:2394002 | pubmed:author | pubmed-author:GeorgeBB | lld:pubmed |
| pubmed-article:2394002 | pubmed:author | pubmed-author:OhmanE MEM | lld:pubmed |
| pubmed-article:2394002 | pubmed:author | pubmed-author:TopolE JEJ | lld:pubmed |
| pubmed-article:2394002 | pubmed:author | pubmed-author:StackRR | lld:pubmed |
| pubmed-article:2394002 | pubmed:author | pubmed-author:SigmonK NKN | lld:pubmed |
| pubmed-article:2394002 | pubmed:author | pubmed-author:CandelaRR | lld:pubmed |
| pubmed-article:2394002 | pubmed:author | pubmed-author:AbbottsmithCC | lld:pubmed |
| pubmed-article:2394002 | pubmed:author | pubmed-author:KereiakesDD | lld:pubmed |
| pubmed-article:2394002 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2394002 | pubmed:volume | 82 | lld:pubmed |
| pubmed-article:2394002 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2394002 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2394002 | pubmed:pagination | 781-91 | lld:pubmed |
| pubmed-article:2394002 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:2394002 | pubmed:meshHeading | pubmed-meshheading:2394002-... | lld:pubmed |
| pubmed-article:2394002 | pubmed:meshHeading | pubmed-meshheading:2394002-... | lld:pubmed |
| pubmed-article:2394002 | pubmed:meshHeading | pubmed-meshheading:2394002-... | lld:pubmed |
| pubmed-article:2394002 | pubmed:meshHeading | pubmed-meshheading:2394002-... | lld:pubmed |
| pubmed-article:2394002 | pubmed:meshHeading | pubmed-meshheading:2394002-... | lld:pubmed |
| pubmed-article:2394002 | pubmed:meshHeading | pubmed-meshheading:2394002-... | lld:pubmed |
| pubmed-article:2394002 | pubmed:meshHeading | pubmed-meshheading:2394002-... | lld:pubmed |
| pubmed-article:2394002 | pubmed:meshHeading | pubmed-meshheading:2394002-... | lld:pubmed |
| pubmed-article:2394002 | pubmed:meshHeading | pubmed-meshheading:2394002-... | lld:pubmed |
| pubmed-article:2394002 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2394002 | pubmed:articleTitle | Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. | lld:pubmed |
| pubmed-article:2394002 | pubmed:affiliation | Department of Medicine, Duke University Medical Center, Durham, NC 27710. | lld:pubmed |
| pubmed-article:2394002 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2394002 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2394002 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2394002 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2394002 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2394002 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2394002 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2394002 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2394002 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2394002 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2394002 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2394002 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2394002 | lld:pubmed |
